Stock Track | Ginkgo Bioworks Plummets 5.32% as Baby Switching Allegations Surface at Hospital

Stock Track
2024/12/13

Ginkgo Bioworks Holdings Inc. (DNA), a leading synthetic biology company, witnessed a 5.32% plummet in its stock price on Friday, amidst allegations of a potential baby switching incident at the RS Islam Cempaka Putih hospital.

The stock's decline followed reports of a father, identified as MR, suspecting that the baby he received after his wife's delivery was not their biological child. MR claimed discrepancies in the physical appearance and measurements of the baby compared to the birth certificate details.

While the hospital has denied any baby switching incident, the allegations raise concerns over potential DNA mixups and mishandling of sensitive biological samples. As a biotechnology firm specializing in DNA engineering and synthetic biology, such incidents could potentially damage Ginkgo Bioworks' reputation and investor confidence in the company's operations and practices.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10